Latest news

Thumbnail image for NICE deems Batten disease therapy too costly for NHS use

NICE deems Batten disease therapy too costly for NHS use

The National Institute for Health and Care Excellence has issued draft guidelines concluding that Biomarin’s Brineura is not a cost-effective treatment option for patients with the ultra rare disorder Batten disease.

13th February 2018

Thumbnail image for Scotland endorses five new therapies for NHS use

Scotland endorses five new therapies for NHS use

Five new medicines are to be funded by the NHS in Scotland, bringing new treatment options for cancer, multiple sclerosis and rheumatoid arthritis, as well as a new contraceptive.

13th February 2018

Thumbnail image for Vertex secures US approval for Symdeko

Vertex secures US approval for Symdeko

US regulators have approved Vertex’ Symdeko, a combination of Kalydeco (ivacaftor) and tezacaftor, to treat certain patients with cystic fibrosis (CF).

13th February 2018

Thumbnail image for NICE backs EUSA’s kidney cancer drug Fotivda

NICE backs EUSA’s kidney cancer drug Fotivda

The National Institute for Health and Care Excellence (NICE) has published draft guidelines backing use of EUSA Pharma’s Fotivda as a first-line treatment option for advanced renal cell carcinoma.

12th February 2018

Thumbnail image for NICE asks Tesaro to submit CDF application for Zejula

NICE asks Tesaro to submit CDF application for Zejula

Tesaro has been asked by NICE to submit a proposal for Zejula use on the National Health Service via the Cancer Drugs Fund for maintenance treatment of patients with relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer.

9th February 2018

Previous  --   11 12 13 14 15 16 17 18 19 20   --  Next

Download our apps

Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.

Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.

Download